Look back at pharma news in the week to October 11

13 October 2019

By Barbara Obstoj-Cardwell. Editor

Last week’s deal-making news included Akcea Therapeutics and majority owner Ionis Pharmaceuticals joining forces with US pharma giant Pfizer on cardiovascular and metabolic diseases research. Also, bluebird bio entered into a gene editing deal with Denmark’s Novo Nordisk to tackle hemophilia A. Regulatory news included Swiss giant Novartis announcing that its much-anticipated anti-VEGF treatment Beovu (brolucizumab) for wet age-related macular degeneration had received approval from the Food and Drug Administration. On the M&A front, investors applauded on Thursday when US biotech Ra Pharma agreed to a $2.1 billion takeover offer from Belgium’s UCB.

Akcea inks deal with Pfizer, rebounding after leadership shuffle

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK